Core Insights - Genvor, Inc. has appointed Dr. George Stavrides as Executive Vice President, Business Development & Commercialization to enhance its strategic partnerships and market expansion efforts in sustainable agriculture [1][2] Company Overview - Genvor, Inc. is a biotechnology company focused on developing peptide-based solutions for crop protection and plant health, aiming to promote sustainable agriculture and reduce chemical inputs [4] Leadership Experience - Dr. Stavrides has over 15 years of experience in agrochemicals and biologicals, previously serving as Global Product Management Lead at Syngenta, where he managed over 500 biological product concepts and oversaw more than 50 product launches globally, resulting in a quadrupling of revenues over seven years [2][3] Strategic Focus - Dr. Stavrides will concentrate on expanding Genvor's commercial strategy, including strategic partnerships, licensing agreements, and collaborations with global agricultural companies [1][3] Industry Impact - The appointment of Dr. Stavrides is expected to accelerate Genvor's commercialization efforts and enhance its ability to address unmet grower needs through innovative biological technologies [3]

Core Viewpoint - Navitas Semiconductor is set to report its fourth quarter and full year 2025 financial results on February 24, 2026, with a conference call scheduled to discuss these results and the company's business outlook [1]. Group 1: Financial Results Announcement - The financial results will be reported after market close on February 24, 2026 [1]. - A conference call will be hosted by the President and CEO, Chris Allexandre, and CFO, Todd Glickman at 2:00 p.m. Pacific Time [1]. Group 2: Conference Call Details - Analysts and investors can join the conference call using the toll-free dial-in numbers: 1-800-715-9871 or 1-646-307-1963, with Conference ID 4101022 [2]. - A live and archived audio webcast of the conference call will be available on the company's Investor Relations website [2]. Group 3: Company Overview - Navitas Semiconductor is a leader in next-generation power semiconductors, focusing on gallium nitride (GaN) and silicon carbide (SiC) technologies [3]. - The company has over 30 years of combined expertise in wide bandgap technologies and holds more than 300 patents issued or pending [3]. - Navitas is recognized as the world's first semiconductor company to achieve CarbonNeutral certification [3].

Financial Performance - The Progressive Corporation reported net premiums written of $6,313 million for December 2025, a 6% increase from $5,964 million in December 2024 [1] - Net premiums earned rose to $7,121 million in December 2025, up 6% from $6,717 million in December 2024 [1] - The company achieved a net income of $1,147 million for December 2025, reflecting a 22% increase compared to $942 million in December 2024 [1] - Earnings per share available to common shareholders increased to $1.95, a 22% rise from $1.60 in December 2024 [1] - Total pretax net realized gains on securities were $168 million in December 2025, a significant recovery from a loss of $140 million in December 2024 [1] - The combined ratio for December 2025 was 87.1%, up 3.0 percentage points from 84.1% in December 2024 [1] Policy Growth - The total number of policies in force reached 38,619 thousand by December 31, 2025, marking a 10% increase from 34,952 thousand in December 2024 [1] - Personal lines policies increased to 37,428 thousand, an 11% growth from 33,811 thousand in December 2024 [1] - Agency auto policies rose by 10% to 10,787 thousand, while direct auto policies grew by 14% to 15,993 thousand [1] - Special lines policies increased by 7% to 6,998 thousand, and property policies rose by 4% to 3,650 thousand [1] - Commercial lines policies saw a 4% increase, reaching 1,191 thousand [1]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. is initiating the regulatory process to gain access to the U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses [1][5]. Group 1: Company Developments - The company has exercised its option with Florida State University to negotiate an exclusive license for large-scale purification techniques to extract castanospermine from Australian Chestnut seeds [1]. - Since signing the option agreement in April 2025, the company has conducted safety testing on Australian Chestnut Extract and developed various prototype capsule formulations for oral delivery [5]. - 60 Degrees Pharmaceuticals specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA, in 2018 [6]. Group 2: Product Information - Castanospermum australe, the source of castanospermine, is primarily found in Queensland and New South Wales, Australia, as well as in Florida, Hawaii, and California [2]. - Castanospermine has been shown to modulate carbohydrate metabolism and impact disease outcomes in animal models through immunomodulation [3]. - It is also a metabolite of celgosivir, which has been evaluated in clinical trials against HIV and Hepatitis C, suggesting castanospermine's safety and activity against similar pharmacological targets [4].

• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein standards and affinity reagents position the organizations to probe disease-associated proteof ...

San Diego, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- California BanCorp (“us,” “we,” “our,” or the “Company”) (NASDAQ: BCAL), the holding company for California Bank of Commerce, N.A. (the “Bank”) announces its consolidated financial results for the fourth quarter and full year of 2025. The Company reported net income of $16.4 million, or $0.50 per diluted share, for the fourth quarter of 2025, compared to $15.7 million, or $0.48 per diluted share for the third quarter of 2025, and $16.8 million, or $0.51 p ...

IRVING, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, announced the appointment of Mike Shufeldt as Chief Revenue Officer (CRO), XBP Americas. In this role, Mr. Shufeldt will lead the revenue strategy and commercial execution, supporting the company’s strategic shif ...

Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line with BioNTech’s strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie ...

LAS VEGAS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (Nasdaq: RR), (“Richtech Robotics” or the “Company”), a Nevada-based provider of AI-driven service robots, announced today that it has entered into a definitive agreement with a fundamentally driven institutional investor for the purchase and sale of 8,500,000 shares of the Company’s Class B common stock in a private placement priced at the market under Nasdaq rules. The private placement is expected to close on or about January 29, 2026, s ...

Attendees Invited to Experience Integer’s New Booth #3201PLANO, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 – 5. Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company’s full range of customer solutions. On prominent display will be R&D Velocity, Integer’s ...